George Demetri

George Demetri (board member) discloses dealings in Blueprint Medicines Corp to SEC (Form 4). We count 20 filings; the first trade dates from 27 February 2018 and the latest from 21 June 2022.

The open-market side counts 1 purchase for €702 alongside 15 sales for €1.4M. Taken together, the sales exceed the purchases by €1.4M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 3 share grants and 1 option exercise. So far in 2022, the count stands at 1 purchase and 1 sale.

Most recently, on 30 June 2022, the filings show an open-market sale worth €531 in Blueprint Medicines Corp. The last insider purchase was made public on 30 June 2022, 1,593 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.